GRFS Grifols SA
Company Analysis
Latest News
Grifols SA Q2 2026 Earnings Preview: What Analysts Expect on July 27, 2026
Grifols is expected to report consensus revenue of $2.22 billion and an EPS of $0.28, with the stock currently trading at $7.61 compared to an average analyst...
🟢 Grifols is trading 4.2% up today amid broader risk-on sentiment
Grifols is trading at $7.58 (+4.20%) amid broader risk-on sentiment as the U.S. session continues. • The upward move appears to be taking place without a...
Grifols splits U.S. biopharma unit, seeking higher margins and independence
Grifols is reorganizing its global operations to grant subsidiaries greater financial and operational independence. The plan creates a standalone structure for...
🟢 GRFS is trading 5.9% up today on Phase 3 trial milestone
GRFS is trading at $7.50 (+5.9%) after-hours following news that the company dosed the first patient in its SWIFT-SC Phase 3 trial for a self-administered...
Grifols Doses First Patient in Phase 3 Trial, Targeting Self-Administered Treatment
Grifols dosed the first patient in its global SWIFT-SC Phase 3 clinical trial. This study evaluates a new subcutaneous formulation of Alpha1-Proteinase...
Grifols votes on 50% capital expansion, targeting US Nasdaq listing
Grifols SA convenes its Annual General Shareholders’ Meeting today, June 18, 2026. Shareholders will vote on key board resolutions during this second-call...